[
  {
    "question": "Excessive daytime sleep and increasing in eating habits:",
    "option_a": "SSRI",
    "option_b": "Methylphenidate",
    "option_c": "Sodium oxybate",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "This question appears to target a presentation of atypical depression, which is classically associated with hypersomnia (excessive daytime sleep) and hyperphagia (increased eating habits). In atypical depression, patients often display mood reactivity along with these reversed vegetative symptoms, contrasting with melancholic depression (where insomnia and anorexia are more common). Atypical depression is believed to involve distinct neurochemical imbalances, including alterations in serotonergic, noradrenergic, and dopaminergic pathways. These changes contribute to the dysregulation of sleep and appetite. While the exact molecular mechanism remains complex, the altered serotonergic tone supports the effectiveness of SSRIs as a treatment modality, as these medications help rebalance these neurotransmitter systems. Patients with atypical depression typically complain of excessive daytime sleepiness and increased appetite (often leading to weight gain), along with mood reactivity. Recognizing these symptoms is crucial since they may be mistakenly attributed solely to sleep disorders. A thorough psychiatric evaluation helps differentiate atypical depression from other conditions with overlapping features such as narcolepsy or sleep disorders like Kleine-Levin syndrome. The diagnosis of atypical depression is clinical, based on history and symptomatology. Differential diagnoses include narcolepsy (which can have excessive sleepiness, but usually does not present with hyperphagia), sleep apnea, and even some endocrine disorders. A detailed patient history, clinical interview, use of standardized rating scales, and sometimes laboratory investigations to rule out metabolic causes are important steps. The current guideline recommendations for atypical depression favor first-line treatment with SSRIs (such as fluoxetine, sertraline, or citalopram). Cognitive behavioral therapy and lifestyle modifications are also valuable. In cases where patients are pregnant or lactating, careful selection of an SSRI known for a strong safety profile (e.g., sertraline) is recommended, with close monitoring. Second-line options might include SNRIs or atypical antipsychotics as adjunctive treatments if needed. Option A (SSRI) is correct because SSRIs target the underlying neurotransmitter imbalance in atypical depression. Option B (Methylphenidate) is a stimulant used primarily for disorders like narcolepsy and ADHD and does not address depressive symptoms. Option C (Sodium oxybate) is indicated in narcolepsy with cataplexy and is not a treatment for depressive disorders with atypical features. 1) Remember that hypersomnia and hyperphagia are hallmark features of atypical depression. 2) SSRIs are considered first-line treatment in atypical depression. 3) Proper differentiation from other sleep disorders is critical given overlapping symptoms. Recent meta-analyses support the efficacy of SSRIs in atypical depression, with current guidelines emphasizing personalized treatment approaches. Ongoing research is investigating the nuances of neurotransmitter dysregulation in mood disorders, reinforcing the rationale for serotonergic agents as first-line therapy.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Pregnant lady with hyperemesis gravidarum, has paresthesia in lower limbs, nystagmus and ataxia:",
    "option_a": "Vitamin B1",
    "option_b": "Vitamin B12",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "This question describes a pregnant woman with hyperemesis gravidarum who presents with neurological signs such as paresthesia in the lower limbs, nystagmus, and ataxia. These symptoms are indicative of Wernicke\u2019s encephalopathy, which is caused by an acute deficiency of thiamine (Vitamin B1). Hyperemesis gravidarum can lead to significant nutritional deficiencies. Thiamine is an essential cofactor for enzymes involved in cerebral energy metabolism (e.g., pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase). Its deficiency results in impaired glucose metabolism and focal lesions, particularly in the mammillary bodies, thalamus, and cerebellum, leading to the classic neurologic manifestations of Wernicke\u2019s encephalopathy. The clinical presentation of Wernicke\u2019s encephalopathy typically includes a triad of ophthalmoplegia or nystagmus, ataxia, and mental status changes. In a pregnant woman with prolonged vomiting (hyperemesis), thiamine deficiency should be suspected since it can rapidly develop in the context of nutritional depletion. The diagnosis of Wernicke\u2019s encephalopathy is primarily clinical. Differential diagnoses include cerebellar degeneration, multiple sclerosis, and other nutritional deficiencies (such as Vitamin B12 deficiency causing subacute combined degeneration). However, the acute setting of hyperemesis makes thiamine deficiency the most likely culprit. Immediate treatment is generally recommended without waiting for laboratory confirmation. The latest guidelines advise prompt administration of intravenous thiamine (Vitamin B1) as first-line therapy, often before any dextrose-containing fluids are given. In pregnancy, IV thiamine is safe and critical to prevent irreversible neurological damage. Magnesium may also be supplemented as it is a cofactor for thiamine-dependent enzymes. Monitoring and supportive care are essential. Option A (Vitamin B1) is correct because the symptoms are consistent with thiamine deficiency related to hyperemesis gravidarum. Option B (Vitamin B12) is incorrect; while B12 deficiency can cause neuropathy and ataxia, its clinical manifestation (subacute combined degeneration) rarely includes nystagmus and is typically associated with a longer time course, not an acute presentation associated with hyperemesis. 1) In any malnourished patient, especially with hyperemesis gravidarum, always administer thiamine before giving glucose. 2) Wernicke\u2019s encephalopathy is a medical emergency that requires immediate treatment. 3) The classic triad, although not always present in full, should raise strong suspicion of thiamine deficiency. Current clinical guidelines underscore the urgency of treating suspected Wernicke\u2019s encephalopathy, particularly in high-risk populations such as pregnant women with hyperemesis gravidarum. Recent studies stress early thiamine supplementation to avert progression to Korsakoff syndrome, and this remains the standard of care.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Pt came with symptoms of restlessness during night time, improving she\u2019s rubs her feet together (restless leg syndrome) what will you do:",
    "option_a": "iron stores/level",
    "option_b": "Sleep study",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "Restless Legs Syndrome (RLS) is a common sensorimotor disorder characterized by an uncomfortable urge to move the legs, typically worsening during periods of inactivity or at night. The phenomenon of relief with movement, such as rubbing the feet together, is a classic feature. RLS is thought to be linked to dopaminergic dysfunction within the central nervous system, and there is a well-established association with low iron stores. Iron acts as a cofactor for tyrosine hydroxylase, a rate-limiting enzyme in dopamine synthesis; thus, iron deficiency can disrupt normal dopaminergic neurotransmission. Patients with RLS often describe an unpleasant tingling, crawling, or itching sensation in the legs that is temporarily relieved by movement. This constellation of symptoms, particularly presenting at night, can lead to significant sleep disturbances. The evaluation of RLS begins with a thorough clinical history and physical examination. Differential diagnoses include peripheral neuropathy, nocturnal leg cramps, and akathisia. The first step in workup, as recommended by many guidelines, is measurement of iron stores (serum ferritin levels) since iron deficiency is a common and potentially reversible cause of RLS. According to current guidelines, initial management of RLS should include assessment and correction of iron deficiency with oral or intravenous iron supplementation if low ferritin levels are detected. First-line pharmacological treatments for patients without significant iron deficiency include dopamine agonists (such as pramipexole or ropinirole) or alpha-2-delta calcium channel ligands (such as gabapentin). In pregnancy, iron supplementation is particularly important and safe, with careful monitoring to avoid overwhelming the fetus. Option A (iron stores/level) is correct, as evaluating and correcting iron deficiency is the recommended initial step in managing RLS. Option B (Sleep study) may be considered in cases where there is suspicion of periodic limb movement disorder or other complex sleep disturbances, but it is not the first-line investigation for classic RLS symptoms. 1) Always inquire about iron deficiency in patients with RLS, as even mild deficiencies can worsen symptoms. 2) The urge to move that is relieved by movement is the hallmark of RLS. 3) In pregnant patients, addressing iron deficiency is a safe and effective intervention. Recent consensus guidelines and research studies emphasize the importance of assessing serum ferritin in RLS patients. Evidence supports that iron repletion can lead to significant symptom improvement, and current practices prioritize this evaluation before moving to more advanced or invasive diagnostic tests such as sleep studies.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Pt with history of visual hallucinations, and can\u2019t move from the bed, hx of frequent episodes of falling asleep \u2026 Diagnosis:",
    "option_a": "Narcolepsy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, sudden sleep attacks, and disturbances in REM sleep regulation. Hallmark features often include episodes of cataplexy (sudden loss of muscle tone), sleep paralysis, and hypnagogic/hypnopompic hallucinations (which are often visual). The underlying mechanism in narcolepsy, particularly with cataplexy, is believed to be the loss or dysfunction of hypocretin (orexin)-producing neurons in the lateral hypothalamus. This deficit leads to an unstable regulation of the sleep-wake cycle, causing intrusions of REM sleep characteristics (such as muscle atonia) into wakefulness. Patients with narcolepsy typically experience overwhelming daytime sleepiness with irresistible sleep attacks. The description of visual hallucinations and an inability to move (reflecting either sleep paralysis or cataplexy) supports a diagnosis of narcolepsy. These symptoms usually occur at sleep onset or upon waking, and the hallucinations are formed and vivid. The mainstay of diagnosis involves a detailed sleep history, sleep diaries, and objective testing with overnight polysomnography followed by a Multiple Sleep Latency Test (MSLT). Differential diagnoses include obstructive sleep apnea, which can also produce daytime sleepiness, as well as other neurological disorders that might present with hallucinations. The rapid onset of sleep in a controlled sleep study helps differentiate narcolepsy from these other conditions. First-line treatment for narcolepsy primarily focuses on managing excessive daytime sleepiness, typically with stimulants (e.g., modafinil or methylphenidate). For cataplexy and associated REM-related phenomena, medications like sodium oxybate or certain antidepressants (SSRIs, SNRIs) are used. Special considerations are required for pregnant or lactating patients; for example, modafinil is generally contraindicated during pregnancy due to potential teratogenicity, so clinicians must carefully balance risks and benefits, sometimes opting for non-pharmacologic measures or alternatives with safer profiles. Option A (Narcolepsy) is correct. The combination of visual hallucinations, episodes of sleep attacks, and difficulty moving (suggestive of sleep paralysis or cataplexy) align with a diagnosis of narcolepsy. No other options were provided in this case, but the clinical features unmistakably point in this direction. 1) Hypnagogic hallucinations and sleep paralysis are commonly seen in narcolepsy and help clinch the diagnosis. 2) The loss of orexin/hypocretin neurons is central to the pathogenesis of narcolepsy type 1. 3) Always consider the safety profile of wake-promoting agents in special populations such as pregnant or lactating patients. Recent updates from sleep medicine societies, including the American Academy of Sleep Medicine, underscore the importance of using objective sleep studies like the MSLT for diagnosis. Emerging research continues to explore immunological and genetic factors in narcolepsy, further refining our understanding of its pathophysiology and guiding management strategies.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Pregnancy is a risk Factor for:",
    "option_a": "RLS",
    "option_b": "Periodic limb movement",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "Restless Legs Syndrome (RLS) is a sensorimotor disorder characterized by an urge to move the legs, usually accompanied by uncomfortable sensations that worsen in the evening or at night. Pregnancy, particularly in the third trimester, is a well\u2010recognized risk factor due to hormonal shifts and metabolic demands. The exact mechanism is not fully elucidated, but current evidence implicates dopaminergic dysfunction and disrupted iron metabolism in the central nervous system. In pregnancy, increased estrogen levels and a tendency toward iron deficiency may exacerbate these imbalances, predisposing women to RLS. Pregnant patients with RLS typically complain of painful or tingling sensations in the legs that occur mainly at rest (especially at night) and are transiently relieved by movement. These symptoms can interfere with sleep and daily functioning, which is particularly concerning during pregnancy. The diagnosis of RLS is clinical, based on patient history and symptomatology. Differential diagnoses include Periodic Limb Movement Disorder (PLMD) \u2013 which involves repetitive leg movements during sleep without the associated sensory discomfort \u2013 peripheral neuropathy, or venous disorders. A careful history and, if needed, sleep studies can help differentiate these conditions. First\u2010line management in pregnant patients involves non-pharmacologic measures such as optimizing sleep hygiene and, when indicated, oral iron supplementation if ferritin levels are low. Pharmacotherapy is generally avoided in pregnancy due to potential teratogenic risks; if treatment is necessary, dopamine agonists may be considered with caution. During lactation, medication choices require similar caution and benefit\u2013risk evaluation based on current guidelines. Option A is correct because pregnancy is indeed a risk factor for the development of RLS. Option B is not the best answer; although periodic limb movements may be observed in patients with RLS, pregnancy specifically increases the risk for RLS, not isolated periodic limb movement disorder. Options C and D are not provided. 1. RLS symptoms in pregnancy often peak in the third trimester. 2. Iron deficiency is both common in pregnancy and a known trigger for RLS. 3. Non-pharmacologic management is the preferred initial approach during pregnancy. Recent guidelines and research emphasize the role of iron metabolism and dopaminergic pathways in RLS. Studies have supported the strategy of using iron supplementation and lifestyle modifications as first-line management in pregnant women, reserving pharmacotherapy only for refractory cases after careful risk assessment.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Young adults with nausea & vomiting",
    "option_a": "nalysis, the marked answer cannot be fully appraised but is retained as provided.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Sleep Neurology",
    "explanation": "Nausea and vomiting in young adults can be a presenting feature of various neurological and non-neurological conditions. In neurology, these symptoms may be associated with conditions such as migraine, raised intracranial pressure, or vestibular disorders. However, without clear answer options or context, the intent of the question remains ambiguous. Depending on the underlying condition, the pathophysiological mechanisms can vary. For instance, in migraine, cortical spreading depression and trigeminovascular activation may provoke nausea, whereas increased intracranial pressure can stimulate the brainstem vomiting centers. Young adults presenting with nausea and vomiting warrant a careful history and examination to differentiate benign causes like migraine from life\u2010threatening issues such as intracranial lesions or infections. A thorough workup should include differentiation between gastrointestinal and central nervous system causes. Common differential diagnoses include migraine, vestibular neuritis, meningitis, brain tumors, and even toxic/metabolic disturbances. Neuroimaging (such as MRI or CT scan) and lumbar puncture might be necessary in cases where neurological pathology is suspected. Management depends on the underlying diagnosis. For instance, if migraine is confirmed, first-line treatments may include triptans, NSAIDs, and antiemetics, while raised intracranial pressure would require urgent intervention. In patients who are pregnant or lactating, treatment must be chosen with careful consideration of teratogenicity and drug safety profiles. Due to the incomplete nature of the question and the absence of clearly defined answer choices, it is not possible to rigorously evaluate why the marked answer 'B' would be correct. Without further details or an accompanying option analysis, the marked answer cannot be fully appraised but is retained as provided. 1. Always consider migraine in young adults with recurrent nausea and vomiting. 2. A detailed history and neurological examination are essential in differentiating benign from serious causes. 3. In any patient with new-onset vomiting and neurological symptoms, rule out increased intracranial pressure. Recent research continues to emphasize the importance of early and accurate differentiation between central and peripheral causes of nausea and vomiting. Guidelines advocate for neuroimaging when clinical suspicion for central pathology exists, and emerging data support tailored treatment strategies in special populations such as pregnant and lactating patients.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "45-year-old male with poor sleeping and recent mood changes, early awakening as reported by his wife and they asked about what is true?",
    "option_a": "pharmacotherapy and hypnotic measures have good effects.",
    "option_b": "Sleep hygiene measures always fail.",
    "option_c": "hypnotics measures are effective in sleep apnea",
    "option_d": "Use antipsychotic for depression",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "In the context of depression, especially in middle-aged adults, insomnia is a common and debilitating symptom. Early morning awakening is one of the classic features of depressive insomnia, and treatment often addresses both mood symptoms and sleep disturbances. Depression is associated with alterations in neurotransmitter systems (such as serotonin and norepinephrine) and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. These changes disrupt normal sleep architecture, leading to early morning awakening and poor sleep quality. A 45-year-old male with mood changes and complaints of early awakening fits the clinical picture of depression with comorbid insomnia. The disrupted sleep not only worsens mood symptoms but can also contribute to a cyclical pattern of poor overall functioning. Differential diagnoses include primary insomnia, anxiety disorders, obstructive sleep apnea, and other sleep-related conditions. A full evaluation should include a detailed sleep history, screening for depression and anxiety with validated instruments, and in selected cases, sleep studies to rule out other sleep disorders. Current guidelines recommend a multimodal approach for depression with insomnia. First-line treatment typically involves antidepressant pharmacotherapy (often SSRIs) along with cognitive behavioral therapy for insomnia (CBT-I). Short-term use of hypnotics may be considered for severe insomnia, but these are used cautiously given the risks of dependency. In pregnant or lactating patients, non-pharmacologic interventions (such as CBT-I and sleep hygiene) are especially emphasized due to the potential teratogenic effects of many sleep medications. Option A is correct because a combination of pharmacotherapy (targeting depression) and hypnotic or behavioral measures (targeting insomnia) has robust evidence for improving both mood and sleep quality. Option B is incorrect; while sleep hygiene alone is often insufficient as a sole treatment, it is an important foundational strategy. Option C is incorrect because hypnotics are generally contraindicated in conditions like obstructive sleep apnea, where they might worsen airway obstruction. Option D is incorrect as antipsychotics are not first-line agents for treating depression-related insomnia. 1. Early morning awakening is a hallmark sign of depression. 2. Combined treatment addressing both mood and sleep disturbances leads to better outcomes. 3. CBT-I is highly effective and has a favorable safety profile, especially in vulnerable populations. Recent studies and clinical guidelines continue to support multimodal treatment strategies for depression with insomnia. There is growing evidence for the effectiveness of CBT-I, both as a stand-alone treatment and in combination with pharmacotherapy, emphasizing its role particularly when minimizing drug exposure is a priority (eg, during pregnancy or lactation).",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "45-year-old male with poor sleeping and recent mood changes, early awakening as reported by his wife and they asked about what is true?",
    "option_a": "is correct. It reflects current best practices that recommend a multimodal approach (combining pharmacotherapy and hypnotic/behavioral measures) for patients with depression and insomnia. Option b is incorrect because sleep hygiene is a valuable component of treatment, even if insufficient on its own. Option c is incorrect since hypnotics are generally not indicated for sleep apnea, where they may worsen respiratory compromise. Option d is incorrect because antipsychotics are not first",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Sleep Neurology",
    "explanation": "This case mirrors the previous scenario, highlighting a middle-aged patient with depression and associated insomnia, particularly manifested as early morning awakening. Effective treatment should address both mood dysregulation and sleep disturbance. The interplay between altered neurotransmitter levels and HPA axis dysregulation in depression leads to disturbed sleep patterns. Early morning awakening is one of the clinical manifestations of these underlying pathophysiological changes. Patients with depression frequently experience sleep disturbances that contribute to their overall symptom burden. In this case, the poor sleep quality and resultant daytime impairment underscore the need for a comprehensive treatment strategy. Differential diagnoses include primary insomnia, sleep apnea, and anxiety disorders. A comprehensive evaluation involving a detailed sleep history, mood assessment, and possibly, sleep studies helps pinpoint the exact etiology and guides management. Based on current guidelines, first-line management involves a combination of pharmacotherapy\u2014typically antidepressants that may have sedative properties\u2014and non-pharmacologic interventions such as CBT-I and sleep hygiene optimization. Short-term use of hypnotics can be considered to rapidly improve sleep, but long-term management emphasizes behavioral therapies. In pregnant or lactating patients, non-pharmacologic methods are preferred to avoid risks associated with many sedative agents. Option a is correct. It reflects current best practices that recommend a multimodal approach (combining pharmacotherapy and hypnotic/behavioral measures) for patients with depression and insomnia. Option b is incorrect because sleep hygiene is a valuable component of treatment, even if insufficient on its own. Option c is incorrect since hypnotics are generally not indicated for sleep apnea, where they may worsen respiratory compromise. Option d is incorrect because antipsychotics are not first-line treatments for uncomplicated depression and carry unnecessary risks when used inappropriately. 1. Multimodal therapy yields the best outcomes in depression-related insomnia. 2. CBT-I is an effective, non-pharmacologic intervention that should be incorporated early. 3. Always assess for underlying sleep apnea when considering hypnotic medications. The latest research and clinical guidelines support integrative treatment approaches combining antidepressants and CBT-I. Recent meta-analyses have shown that short-term hypnotic use, when combined with behavioral therapy, can substantially improve sleep outcomes without significantly increasing long-term risk, particularly when alternative non-pharmacologic options are prioritized in sensitive populations.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a DM patient with symptoms suggestive of RLS, next?",
    "option_a": "check Ferritin and iron",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "Restless Legs Syndrome (RLS) is a sensorimotor disorder characterized by an irresistible urge to move the legs, usually accompanied by uncomfortable sensations that worsen during periods of inactivity and in the evening. Iron deficiency, even in the absence of anemia, is a well\u2010recognized secondary cause of RLS. The precise mechanism of RLS is not fully understood, but dysfunction in the central dopaminergic pathways along with impaired iron metabolism in the brain has been implicated. Low iron stores, reflected by decreased ferritin levels, lead to altered dopamine receptor function, thereby precipitating RLS symptoms. In patients with diabetes mellitus, distinguishing between diabetic peripheral neuropathy and RLS is important. RLS has a characteristic presentation with nocturnal symptoms and an urge to move that transiently relieves the discomfort, whereas diabetic neuropathy typically presents with a more constant sensory loss or pain. Checking serum ferritin and iron studies is a critical step in the evaluation and management of RLS. The workup of suspected RLS should include a detailed history and physical examination, with emphasis on the timing and nature of symptoms. Laboratory evaluation, especially serum ferritin and iron studies, is recommended to rule out iron deficiency. Differential diagnoses include peripheral neuropathies (such as diabetic neuropathy), akathisia, and nocturnal leg cramps. In patients with low serum ferritin, iron supplementation is considered first-line management, along with lifestyle modifications such as improved sleep hygiene. If symptoms persist after iron repletion, dopaminergic agents may be indicated. In special populations like pregnant or lactating women, iron supplementation is safe and should be considered a priority to improve both maternal and fetal outcomes. Option A (check Ferritin and iron) is correct because iron deficiency is a modifiable and treatable cause of RLS. Other options (B, C, D) either do not address the underlying potential deficiency or are not part of the initial evaluation strategy. \u2022 Serum ferritin levels below 50 \u00b5g/L, even if within 'normal' range, may be associated with RLS symptoms.  \u2022 Differentiating RLS from diabetic neuropathy in DM patients is essential to ensure proper treatment. Recent guidelines and research continue to support the evaluation of iron status in patients with RLS, emphasizing that iron repletion can significantly reduce symptoms. Updated sleep medicine guidelines recommend initial laboratory screening for iron deficiency as part of the diagnostic algorithm for RLS.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Young female with excessive daytime sleepiness, hyperphagia, and night time sleep issue (I forget) whats tx, no mention of cataplexy or other features of narcolepsy ..etc even no clear feature of kleine levin syndrome",
    "option_a": "(modafinil) is effective in diagnosed narcolepsy and idiopathic hypersomnia, but its use is not justified without established diagnostic criteria. Other options, such as sodium oxybate or traditional stimulants, similarly require a definitive diagnosis before use. Thus, the precise answer is 'None'",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Sleep Neurology",
    "explanation": "Excessive daytime sleepiness (EDS) can result from several sleep disorders including narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome (KLS). In this clinical scenario, while the patient exhibits EDS and hyperphagia, there is an absence of pathognomonic features such as cataplexy (seen in narcolepsy) or the episodic cognitive and behavioral disturbances typical of KLS. Narcolepsy is generally linked to hypocretin (orexin) deficiency in the hypothalamus, whereas idiopathic hypersomnia involves dysregulation of sleep-wake control without the distinct features noted in narcolepsy. KLS, on the other hand, involves periodic episodes of hypersomnia with accompanying hyperphagia and other behavioral disturbances. However, without the classical features or clear episodicity, there is insufficient evidence to label this as any specific well-defined sleep disorder. The lack of specific clinical markers such as cataplexy (for narcolepsy) or recurrent episodes with typical duration and behavior (for KLS) makes the diagnosis unclear. Consequently, initiating a definitive treatment (like modafinil, sodium oxybate, or stimulants) without a precise diagnosis could result in inappropriate management. A thorough sleep history, sleep diary, and polysomnography followed by a Multiple Sleep Latency Test (MSLT) are necessary to differentiate among causes of EDS. Differential diagnoses include obstructive sleep apnea, narcolepsy without cataplexy, idiopathic hypersomnia, and even mood disorders. In unclear cases, a period of observation and further diagnostic evaluations is warranted before initiating treatment. Management should be guided by a confirmed diagnosis. For narcolepsy, modafinil is first-line, while idiopathic hypersomnia might also be managed with stimulants. KLS is managed conservatively with supportive care during episodes. Because a specific diagnosis is lacking here, a cautious approach emphasizing further evaluation rather than empirical treatment is recommended. In pregnant or lactating patients (if applicable), the teratogenic risk of pharmacotherapy must be scrutinized, further underscoring the need for precise diagnosis. Option A (modafinil) is effective in diagnosed narcolepsy and idiopathic hypersomnia, but its use is not justified without established diagnostic criteria. Other options, such as sodium oxybate or traditional stimulants, similarly require a definitive diagnosis before use. Thus, the precise answer is 'None' \u2013 no definitive treatment should be initiated without further diagnostic clarification. \u2022 Always confirm a diagnosis with objective testing (e.g., polysomnography and MSLT) before initiating treatment in sleep disorders.  \u2022 Hyperphagia accompanied by EDS can raise suspicion for KLS, but episodicity and additional behavioral symptoms are key for diagnosis. Current sleep medicine guidelines emphasize a comprehensive diagnostic approach prior to treatment initiation. Recent studies highlight the risk of misdiagnosis and inappropriate treatment when symptoms are managed empirically without full evaluation.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Pregnant lady with hyperemesis gravidarum, presented after 2 weeks with unsteady gait, numbness and sensory disturbances in distal limbs. On exam she has ataxia and nystagmus. What could be the cause?",
    "option_a": "Vitamin B12 \u2193",
    "option_b": "Zink toxicity",
    "option_c": "Thiamine \u2193",
    "option_d": "Folate \u2193",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Sleep Neurology",
    "explanation": "Wernicke's encephalopathy, a neurological emergency resulting from thiamine (vitamin B1) deficiency, often occurs in the context of hyperemesis gravidarum. The classical triad includes ataxia, ophthalmoplegia (or nystagmus), and confusion. Thiamine is an essential cofactor for several enzymatic processes in the brain. Deficiency leads to impaired cerebral energy metabolism and focal lesions in regions such as the mammillary bodies, thalamus, and periaqueductal gray matter which manifest clinically as ataxia, nystagmus, and other neuropsychiatric symptoms. In a pregnant woman with a history of hyperemesis gravidarum, prolonged vomiting predisposes to nutritional deficiencies. The acute onset of unsteady gait, numbness, ataxia, and nystagmus strongly points towards thiamine deficiency and the development of Wernicke's encephalopathy. The diagnosis is primarily clinical, supported by MRI findings and measurement of thiamine levels, though treatment should not be delayed for confirmatory tests. Differential diagnoses include vitamin B12 deficiency (which causes subacute combined degeneration with a more chronic course), zinc toxicity (which may cause copper deficiency myelopathy), and folate deficiency (which does not classically cause these neurological signs). Immediate administration of intravenous thiamine is the treatment of choice. Guidelines recommend administering thiamine before any glucose-containing solutions to prevent exacerbation of the condition. In pregnant patients, prompt thiamine replacement is critical and safe, protecting both maternal and fetal health. Maintenance doses are tailored based on clinical response and laboratory assessments. Option C (Thiamine \u2193) is correct. Vitamin B12 deficiency (Option A) typically produces a more gradual onset of symptoms without acute nystagmus. Zinc toxicity (Option B) and folate deficiency (Option D) do not produce the acute brainstem and cerebellar signs observed in this patient. \u2022 In patients with hyperemesis gravidarum, always administer prophylactic thiamine prior to initiating IV glucose to avoid precipitating Wernicke's encephalopathy.  \u2022 The triad of ataxia, nystagmus, and confusion is a red flag for thiamine deficiency. Recent clinical guidelines emphasize early recognition and treatment of thiamine deficiency in high-risk populations, including pregnant women with hyperemesis, to prevent permanent neurological damage. Studies support the use of high-dose intravenous thiamine given its safety profile in pregnancy.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "65 years old male presents for disturbed behaviour during sleep. His wife stated that this has been going on for many years. He shouts and lashes out violently during sleep, which made the wife sleeps in separate room. Treatment?",
    "option_a": "Levodopa",
    "option_b": "Clonazepam",
    "option_c": "Valproate",
    "option_d": "DBS",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Sleep Neurology",
    "explanation": "REM Sleep Behavior Disorder (RBD) is characterized by the loss of normal muscle atonia during REM sleep, resulting in dream enactment behaviors such as shouting, punching, or lashing out. RBD is believed to result from dysfunction in the brainstem regions that regulate REM atonia, particularly within the sublaterodorsal nucleus. This dysfunction may be an early marker of neurodegenerative diseases such as Parkinson's disease or other synucleinopathies. In older adults, particularly males, RBD can present with complex motor behaviors during sleep leading to injury of the patient or bed partner. The long history of disturbed sleep behavior with violent motor manifestations in this 65-year-old patient is classic for RBD. Diagnosis is primarily clinical, supported by polysomnography which demonstrates REM sleep without atonia. Differential diagnoses include sleepwalking, nocturnal seizures, and obstructive sleep apnea-related parasomnias, each having distinct clinical and polysomnographic features. Clonazepam is the first-line treatment for RBD due to its efficacy in reducing motor behaviors during REM sleep. In patients who have contraindications to benzodiazepines, melatonin is a viable alternative. Although the patient in this case is not pregnant or lactating, it\u2019s important to note that treatment choices may differ in those populations due to safety considerations; for example, melatonin might be preferred over clonazepam in pregnant or breastfeeding individuals if necessary. Option B (Clonazepam) is correct as it is the standard first-line management for RBD. Option A (Levodopa) is indicated primarily in Parkinson's disease and does not address RBD directly. Option C (Valproate) is not supported by evidence for RBD treatment, and Option D (DBS) is only considered in advanced neurodegenerative cases, not as a first-line treatment for isolated RBD. \u2022 RBD may precede other neurodegenerative disorders by several years, so long-term follow-up is recommended.  \u2022 Safety modifications in the patient\u2019s environment are critical to prevent injury due to violent movements during sleep. Recent studies and clinical guidelines continue to support clonazepam as the most effective treatment for RBD. Emerging evidence also points to the potential benefits of melatonin, especially in patients with contraindications to benzodiazepines, though further research is ongoing.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario Patient has difficulty sleeping, he is lying on bed looking at the clock, came with sleep issue next.",
    "option_a": "Melatonin",
    "option_b": "Benzodiazepine",
    "option_c": "zolpidem",
    "option_d": ", although not detailed in the list, is assumed to represent non",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Sleep Neurology",
    "explanation": "Insomnia is a common sleep disorder characterized by difficulty in falling asleep, staying asleep, or non\u2010restorative sleep. Non\u2010pharmacologic measures such as proper sleep hygiene and cognitive behavioral therapy for insomnia (CBT\u2010I) are considered first-line, especially in patients who exhibit behaviors like clock-watching which can exacerbate anxiety about sleep. Insomnia may result from hyperarousal states, maladaptive sleep behaviors, and cognitive factors such as an excessive focus on time (clock-watching) that increases anxiety. This hyperarousal disrupts the normal sleep cycle and impairs the ability to initiate and maintain sleep. Patients with insomnia, particularly those who exhibit behaviors like constantly checking the clock, often experience a heightened state of anxiety that perpetuates sleep difficulties. This clinical picture underscores the importance of non-pharmacologic interventions that address behavioral and cognitive patterns. The evaluation of insomnia is primarily clinical, involving a detailed sleep history, sleep diaries, and identification of stressors or maladaptive behaviors. Differential diagnoses include circadian rhythm disorders, sleep apnea, restless leg syndrome, and psychiatric conditions such as anxiety and depression. First-line management for insomnia is non-pharmacologic. Sleep hygiene education and CBT-I are recommended. Pharmacotherapy (e.g., melatonin, zolpidem, or benzodiazepines) may be used as short-term agents but are not preferred due to risks of dependence and side effects. In pregnant or lactating patients, CBT-I is particularly encouraged due to minimal risk, while melatonin\u2019s use is approached with caution. Option A (Melatonin) is useful in circadian rhythm disturbances rather than primary insomnia with clock-watching behavior. Option B (Benzodiazepine) can cause dependence and is not first-line. Option C (Zolpidem) is a short-term nonbenzodiazepine hypnotic but still is a pharmacologic approach. Option D, although not detailed in the list, is assumed to represent non-pharmacologic management (sleep hygiene/CBT-I), which aligns best with current guidelines. 1. Non-pharmacologic measures are considered first-line in managing insomnia. 2. Clock-watching can reinforce anxiety and perpetuate insomnia. 3. CBT-I has robust evidence supporting its efficacy without the side effects of medication. Recent guidelines from the American Academy of Sleep Medicine emphasize CBT-I and sleep hygiene as the cornerstone of chronic insomnia management. Emerging studies continue to support the long-term benefits of non-pharmacologic therapies over pharmacotherapy.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "43-year-old man presents with complaints of unrefreshing sleep and excessive daytime sleepiness, snoring at night, best next step.",
    "option_a": "EEG",
    "option_b": "Polysomnogram",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Sleep Neurology",
    "explanation": "Obstructive sleep apnea (OSA) is a sleep-related breathing disorder marked by repeated episodes of upper airway obstruction during sleep. The hallmark symptoms include excessive daytime sleepiness, snoring, and non-restorative sleep. OSA occurs due to collapse of the pharyngeal airway during sleep, leading to intermittent hypoxemia and arousal from sleep. This cyclical pattern contributes to cardiovascular stress and metabolic disturbances through sympathetic nervous system activation. A 43-year-old man with unrefreshing sleep, daytime sleepiness, and snoring raises high suspicion for OSA. These clinical manifestations directly correlate with the nocturnal airway obstruction typical of the disorder. The diagnostic test of choice for OSA is an overnight polysomnogram, which evaluates the apnea-hypopnea index (AHI) to grade severity. Differential diagnoses include narcolepsy (with features of sudden sleep attacks and cataplexy), insomnia, and central sleep apnea. A detailed history and sleep study help to differentiate these conditions. First-line management of OSA includes lifestyle modifications such as weight loss, positional therapy, and the use of continuous positive airway pressure (CPAP) devices. In cases where CPAP is poorly tolerated, oral appliances or surgical interventions may be considered. In pregnancy, CPAP remains the mainstay of treatment for moderate to severe OSA while monitoring fetal well\u2010being. Option A (EEG) is not useful for diagnosing sleep-disordered breathing, as it assesses brain electrical activity rather than respiratory parameters. Option B (Polysomnogram) is the gold standard for diagnosing OSA, making it the correct and most useful next step. 1. Polysomnography is the definitive diagnostic tool for OSA. 2. Excessive daytime sleepiness and loud snoring are classic clinical clues. 3. CPAP is the mainstay of therapy, including in pregnant patients when indicated. Recent guidelines and research support the use of CPAP as first-line therapy in moderate-to-severe OSA, with ongoing studies exploring alternative therapies and the cardiovascular benefits of effective OSA treatment.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Young man who went to sleep at 10 PM woke up at midnight with weakness in his whole body and SOB attack resolved after few hours. What is the mechanism of action of treatment of this condition (same previous scenario that was asking about what test to do)?",
    "option_a": "Cholinesterase.",
    "option_b": "Carbonic anhydrase.",
    "option_c": "Hypokalemic",
    "option_d": "Rest",
    "option_e": "Severe attack",
    "correct_answer": "B",
    "subspecialty": "Sleep Neurology",
    "explanation": "Periodic paralysis is a group of neuromuscular disorders characterized by transient episodes of muscle weakness. Hypokalemic periodic paralysis, in particular, is often due to underlying channelopathies affecting ion channels in muscle membranes. In hypokalemic periodic paralysis, mutations in voltage-gated ion channels (typically calcium or sodium channels) lead to abnormal ion conductance. This causes episodic shifts in potassium distribution, resulting in transient muscle weakness. Prophylactic treatment with acetazolamide, a carbonic anhydrase inhibitor, is thought to help by inducing mild acidosis and stabilizing membrane excitability, though the precise mechanism remains incompletely understood. A young man experiencing sudden nocturnal onset of whole-body weakness with spontaneous resolution fits the clinical picture of hypokalemic periodic paralysis. The clinical course\u2014with preserved cranial nerve and respiratory muscle function\u2014supports this diagnosis. Diagnosis is typically confirmed by documenting low serum potassium levels during an attack, alongside a suggestive history and, in some cases, specialized electrophysiologic tests. The differential diagnosis includes hyperkalemic periodic paralysis and secondary causes (e.g., thyrotoxic periodic paralysis), with thyroid function tests often aiding in differentiation. Acute management involves careful potassium supplementation. For prophylaxis, acetazolamide (a carbonic anhydrase inhibitor) is considered first-line therapy. In pregnant or lactating women, acetazolamide is used with caution (typically categorized as FDA pregnancy Category C) and risks versus benefits must be carefully weighed. Option A (Cholinesterase) is used in conditions like myasthenia gravis and does not apply here. Option B (Carbonic anhydrase) correctly identifies the mechanism of action of acetazolamide, the standard prophylactic agent for hypokalemic periodic paralysis. Options C (Hypokalemic), D (Rest), and E (Severe attack) do not describe a mechanism of action. 1. Hypokalemic periodic paralysis often presents with transient, reversible weakness typically sparing bulbar and respiratory muscles. 2. Acetazolamide can effectively reduce the frequency of attacks via its carbonic anhydrase inhibiting properties. 3. Monitoring potassium levels during attacks is crucial to avoid complications. Recent research continues to support the use of acetazolamide as an effective prophylactic measure. Studies are also exploring genetic markers and individualized treatment strategies to better tailor therapy in patients with channelopathies.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A young man came to ER who went to sleep at 10 Pm woke up at midnight with weakness in his whole body and resolved after few hours, hx is recurrent with sparing of cranial nerves and respiratory muscles what is the most useful test to be done? (? periodic paralysis scenario no hx of carbohydrate of potassium or exercise in the q)",
    "option_a": "short exercise test",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "Periodic paralysis, a type of muscle channelopathy, presents with episodic muscle weakness. The evaluation of such patients may include electrophysiologic testing to assess changes in muscle membrane excitability. In these disorders, mutations affecting ion channels lead to abnormal muscle excitability that can be provoked by exercise. Electrophysiologic studies (exercise tests) evaluate how the compound muscle action potentials (CMAPs) change with or after exercise, which aids in distinguishing channelopathies from other neuromuscular conditions. A young man with recurrent episodes of whole-body weakness, with sparing of cranial and respiratory muscles, is highly suggestive of a primary periodic paralysis. Since serum potassium levels might normalize between attacks, specialized electrophysiologic tests can help confirm the diagnosis. The most immediate and useful diagnostic approach in suspected periodic paralysis typically includes measurement of serum electrolytes during an attack. However, if the patient presents between attacks, an electrophysiologic exercise test is indicated. The short exercise test, which involves brief maximal contraction and subsequent measurement of CMAPs, can reveal characteristic abnormalities in muscle excitability. Acute management is directed at restoring normal potassium levels during an attack, while prophylactic treatment (for example, with acetazolamide) is used to decrease attack frequency. In pregnant or lactating patients, careful evaluation of therapy (including the use of acetazolamide) is essential given potential risks. Option A (Short exercise test) is a recognized electrophysiologic tool that assesses changes in muscle excitability and is useful in diagnosing periodic paralysis. Option B, which is marked, is blank and does not offer any diagnostic information, making it incorrect. Options C and D are similarly non-diagnostic in this context. 1. Electrophysiologic exercise tests can be valuable when serum electrolyte measurements are inconclusive between attacks. 2. The short exercise test is a practical tool to evaluate muscle membrane excitability in suspected channelopathies. 3. Always correlate electrophysiologic findings with the clinical history for accurate diagnosis. Current research supports the utility of exercise testing (both short and long protocols) in diagnosing channelopathies, though the short exercise test is often more readily performed in a clinical setting. Ongoing studies aim to refine these tests to improve sensitivity and specificity in different subtypes of periodic paralysis.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Which of the following electrodiagnostic tests is most helpful in the diagnosis of periodic paralysis?",
    "option_a": "high-frequency repetitive stimulation",
    "option_b": "long exercise testing",
    "option_c": "low-frequency repetitive stimulation",
    "option_d": "short exercise testing",
    "option_e": "single fiber EMG",
    "correct_answer": "B",
    "subspecialty": "Sleep Neurology",
    "explanation": "Periodic paralysis refers to a group of rare skeletal muscle channelopathies (e.g., hypokalemic and hyperkalemic periodic paralysis) characterized by episodic muscle weakness. The long exercise test is designed to reveal defects in muscle membrane excitability by monitoring the compound muscle action potential (CMAP) over a period of sustained exercise. In periodic paralysis, mutations in ion channels (typically calcium or sodium channels) lead to abnormal ion fluxes during or after sustained muscle activity. This can result in a decrement in the amplitude of the CMAP after prolonged exercise. The long exercise test assesses the delayed recovery and the characteristic abnormal response of the muscle membrane. Patients typically present with episodic muscle weakness that may be triggered by exercise, rest after strenuous activity, or metabolic factors. The long exercise test helps differentiate these channelopathies from other neuromuscular disorders by demonstrating an abnormal electrical response that correlates with the episodic weakness. Differential diagnoses include neuromuscular junction disorders (e.g., myasthenia gravis, which is evaluated with repetitive stimulation tests) and myotonic disorders. The long exercise test is more specific for periodic paralysis, whereas other tests like single-fiber EMG or high/low-frequency repetitive stimulation are more pertinent to other conditions. Management involves supportive care during acute attacks (e.g., potassium supplementation for hypokalemic forms) and preventive measures such as lifestyle modifications and avoidance of triggers. Carbonic anhydrase inhibitors (e.g., acetazolamide) are considered first-line preventatives. For pregnant or lactating women, potassium management and careful medication selection (using agents with favorable pregnancy categories) are essential. Option A (high-frequency repetitive stimulation) and Option C (low-frequency repetitive stimulation) are used primarily in the evaluation of neuromuscular junction disorders, not channelopathies. Option D (short exercise testing) is more associated with evaluating myasthenic weakness. Option E (single fiber EMG) is used in diagnosing neuromuscular junction transmission defects and is not the test of choice for periodic paralysis. Thus, Option B (long exercise testing) is the correct choice. 1. The long exercise test is highly valuable in diagnosing periodic paralysis by exposing the hallmark decrement in muscle action potential amplitude. 2. Distinguishing periodic paralysis from myasthenia gravis is essential since the diagnostic electrodiagnostic tests differ drastically between these conditions. Recent studies underscore the long exercise test's sensitivity and specificity in detecting subtle ion channel dysfunctions. Updated clinical guidelines continue to reinforce its role in the diagnostic workup of suspected periodic paralysis cases.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Question described symptomatic palatal myoclonus and asked what to do (not improved with sleep)?",
    "option_a": "MRI brain",
    "option_b": "EEG",
    "option_c": "CT jaw",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "Palatal myoclonus is characterized by rhythmic contractions of the soft palate. It is categorized into essential and symptomatic forms, with symptomatic palatal myoclonus usually being secondary to identifiable lesions in the brainstem or cerebellum. Symptomatic palatal myoclonus is most often due to lesions affecting the Guillain-Mollaret triangle\u2014a neural pathway connecting the red nucleus, inferior olivary nucleus, and the dentate nucleus. Damage in this pathway can lead to hypertrophic olivary degeneration, which manifests as persistent myoclonic movements. Patients with symptomatic palatal myoclonus present with involuntary, rhythmic movements of the soft palate that do not diminish during sleep, contrary to essential palatal myoclonus. The persistence of symptoms regardless of sleep signals an underlying structural abnormality. The primary diagnostic modality is an MRI of the brain, which can identify lesions in the brainstem or cerebellum \u2014 particularly in the region of the dentato-rubro-olivary pathway. Differential diagnoses include essential palatal myoclonus (which may improve with sleep) and other movement disorders that may mimic palatal myoclonus. The initial step is to perform a high-resolution MRI of the brain to locate any structural lesions. Once identified, management should be directed toward treating the underlying pathology. In pregnant or lactating women, MRI without gadolinium contrast is often preferred unless absolutely indicated, as contrast agents are generally avoided or used with caution. Option A (MRI brain) is correct because it is the best method to evaluate for structural causes such as lesions in the brainstem. Option B (EEG) is not appropriate for diagnosing palatal myoclonus unless there is a suspicion of seizure activity. Option C (CT jaw) is irrelevant to the localization of a neurological lesion related to palatal myoclonus. 1. Symptomatic palatal myoclonus does not improve with sleep, which is a key differentiator from its essential counterpart. 2. Always investigate for structural lesions using MRI when palatal myoclonus is persistent and symptomatic. Current neuroradiology guidelines advocate the use of MRI as the imaging modality of choice in detecting brainstem lesions. Recent research emphasizes the role of the Guillain-Mollaret triangle in the pathogenesis of symptomatic palatal myoclonus.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "(repeated 3 times!) Abnormal accumulation of which protein is found in ALS/FTD COMPLEX",
    "option_a": "TDP 43",
    "option_b": "Tau",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia) represent a spectrum of neurodegenerative disorders. A significant molecular link between them is the abnormal accumulation of TDP-43 protein, which is seen in the majority of these cases. TDP-43 is a nuclear protein involved in RNA regulation. In ALS/FTD, this protein misfolds, becomes hyperphosphorylated, and aggregates in the cytoplasm of neurons and glial cells, leading to neuronal dysfunction and cell death. This pathological process is a hallmark of the ALS/FTD spectrum, distinguishing it from other neurodegenerative conditions. Clinically, patients with ALS/FTD may present with features of motor neuron degeneration (progressive weakness, spasticity) alongside cognitive and behavioral changes. The presence of TDP-43 aggregates helps explain the overlapping clinical phenotypes observed. Definitive diagnosis of TDP-43 pathology is made postmortem via immunohistochemical staining. Clinically, the diagnosis is built upon a combination of neurological examination, imaging, and sometimes biomarkers; differentiating ALS/FTD from other dementias (such as those with tau pathology) is paramount. Currently, management is largely supportive and symptomatic. While there are some modest disease-modifying therapies in ALS, treatment is focused on maintaining function and quality of life. In patients who are pregnant or lactating, treatment options are limited and must be weighed carefully against potential risks to the fetus or infant. Option A (TDP 43) is the correct answer since TDP-43 is the abnormal protein typically found in the ALS/FTD complex. Option B (Tau) is more associated with other neurodegenerative diseases such as Alzheimer's disease and certain types of frontotemporal dementia but is not the hallmark pathology in the ALS/FTD spectrum. 1. TDP-43 proteinopathy is a unifying feature in the majority of ALS and many FTD cases. 2. Recognizing the molecular pathology can aid in the development of potential future targeted therapies. Recent research highlights TDP-43\u2019s central role in neurodegeneration in ALS/FTD. Emerging therapies are currently being investigated to target the pathological aggregation and propagation of TDP-43, though no specific TDP-43 directed treatment is yet established.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A woman who had repeating episodes of vomiting for one month visited ER and given omeprazole, and had visual changes in both eye with some time apart, now she presented with symptoms of TM what is the diagnosis?",
    "option_a": "NMO",
    "option_b": "MS",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Sleep Neurology",
    "explanation": "Neuromyelitis optica (NMO), also known as Devic's disease, is an autoimmune demyelinating disorder primarily affecting the optic nerve and spinal cord. A key clinical feature can be area postrema syndrome, which presents as unexplained nausea and vomiting. NMO is most often associated with antibodies against aquaporin-4 (AQP4-IgG). The immune-mediated attack on astrocytes leads to demyelination and necrosis in the optic nerves and spinal cord. Involvement of the area postrema in the medulla can cause persistent vomiting and nausea. This patient\u2019s history of repeated vomiting likely represents area postrema syndrome. The subsequent bilateral visual changes suggest optic neuritis, and the later development of symptoms of transverse myelitis (TM) aligns with the classic presentation of NMO. Diagnosis is based on clinical criteria supported by imaging and serological assays. MRI of the brain and spinal cord reveals longitudinally extensive transverse myelitis and optic nerve lesions. AQP4-IgG testing is crucial. Differential diagnoses include multiple sclerosis (MS), which typically exhibits shorter spinal cord lesions, and other causes of TM. Acute attacks are managed with high-dose intravenous corticosteroids, often followed by plasmapheresis if there is an inadequate response. Long-term immunosuppressive therapy (e.g., azathioprine, mycophenolate mofetil, or rituximab) is recommended to prevent relapses. In pregnancy and lactation, corticosteroids remain the mainstay for acute management, and certain immunosuppressants (such as azathioprine) may be considered with careful risk-benefit counseling, whereas drugs like mycophenolate mofetil are contraindicated due to teratogenicity. Option A (NMO) is the correct answer because the clinical features (intractable vomiting indicative of area postrema syndrome, optic neuritis, and transverse myelitis) are classic for neuromyelitis optica. Option B (MS) is less likely given the specific association with area postrema symptoms and the typical pattern of spinal cord involvement in NMO, which is more extensive than in MS. 1. Intractable vomiting in a young woman with subsequent optic neuritis and TM should prompt evaluation for NMO. 2. The presence of area postrema syndrome is a red flag for NMO rather than MS. Recent revisions in the diagnostic criteria for NMOSD emphasize early antibody testing (AQP4-IgG) and MRI findings to distinguish NMO from MS. Ongoing clinical trials are evaluating newer immunotherapies to reduce relapse rates and long-term disability in NMO patients.",
    "exam_year": "2020",
    "exam_type": "Part II"
  }
]